Singapūra - angļu - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - selexipag - tablet, film coated - selexipag 1.2 mg

Singapūra - angļu - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - selexipag - tablet, film coated - selexipag 1.4 mg

Singapūra - angļu - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - selexipag - tablet, film coated - selexipag 1.6 mg

Singapūra - angļu - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - selexipag - tablet, film coated - selexipag 0.4 mg

Singapūra - angļu - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - selexipag - tablet, film coated - selexipag 0.6 mg

Singapūra - angļu - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - selexipag - tablet, film coated - selexipag 0.8 mg

Eiropas Savienība - angļu - EMA (European Medicines Agency)

janssen cilag international nv - selexipag - hypertension, pulmonary - antithrombotic agents - uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (pah) in adult patients with who functional class (fc) ii–iii, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (era) and/or a phosphodiesterase type 5 (pde-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies. efficacy has been shown in a pah population including idiopathic and heritable pah, pah associated with connective tissue disorders, and pah associated with corrected simple congenital heart disease.,

Kanāda - angļu - Health Canada

janssen inc - selexipag - tablet - 200mcg - selexipag 200mcg - vasodilating agents

Kanāda - angļu - Health Canada

janssen inc - selexipag - tablet - 400mcg - selexipag 400mcg - vasodilating agents

Kanāda - angļu - Health Canada

janssen inc - selexipag - tablet - 600mcg - selexipag 600mcg - vasodilating agents